The two companies to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer’s disease (AD)

https://www.novartis.com/news/media-releases/novartis-and-amgen-announce-expanded-collaboration-banner-alzheimers-institute